Acadia Pharmaceuticals Inc.

Cadent Therapeutics, Inc.

Magnus Gustafsson

Roger Olsson

Lene Hyldtoft

Birgitte Winther Lund

Fabrice Piu

Vladimir Sherbukhin

John Adams Lowe, Iii

John Michael McCall

Carl-Magnus A Andersson

Birgitte Langer Eriksen

Gregg F Keaney

Martin R Jefson

Janus Schreiber Larsen

Charlotte Hougaard

Dorte Strøbæk

Thomas Amos Jacobsen

Jessica Klein

Brigitte Winther Lund

Kent R I Olsson

Nadia Lybøl Von Schoubye

Birgitte Lund

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

Disclosed herein are novel di-aromatic compounds of the general formula (I). Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed. 

Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta

Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof.

Compounds with activity at estrogen receptors

Disclosed herein are compounds of Formula I as disclosed herein, methods of modulating the activity of an estrogen receptor and methods of treating a disorder associated with estrogen receptors.

Disclosed herein are novel di-aromatic compounds and methods for using various di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors.

Described is method for preparing tertiary amines comprising sequential, exhaustive alkylation of a hydroxylamine derivative and cleavage of the O&#x2014;N bond using the following steps:

Solid phase parallel synthesis of tertiary amines

Growing community of inventors

Frederiksberg, Denmark

Magnus Gustafsson